参考文献/References:
[1] MILLER P D,ADACHI J D,ALBERGARIA B H,et al.Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease[J].J Bone Miner Res,2022,37(8):1437-1445.
[2] 中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J].中华骨质疏松和骨矿盐疾病杂志,2019,12(4):317-318.
[3] EBINA K,ETANI Y,TSUBOI H,et al.Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis[J].Osteoporos Int,2022,33(8):1807-1813.
[4] 蔡毅,赵继荣,陈文,等.基于“肾主骨生髓”理论综述骨髓间充质干细胞与绝经后骨质疏松的关系[J].中国骨质疏松杂志,2021,27(11):1666-1670.
[5] 颜宇轩,何滨锣.绝经后骨质疏松的用药规律及作用机制探讨[J].中医临床研究,2020,12(31):29-33.
[6] KALU D N.The ovariectomized rat model of postmenopausal bone loss[J].Bone Miner,1991,15(3):175-191.
[7] 石敏,赵继荣,薛旭,等.基于“脾主肉、肾主骨”理论探讨绝经后骨质疏松症的OPG/RANK/RANKL信号调控机制[J].中国骨质疏松杂志,2019,25(9):1336-1339.
[8] 招文华,尚奇,余富勇,等.从肾-脑-骨生物轴探讨老年性骨质疏松症海马-下丘脑-垂体-性腺轴失衡的神经内分泌机制[J].中华中医药杂志,2022,37(10):5735-5738.
[9] 唐宇,肖丹,刘子毓,等.龟甲胶的研究现状及展望[J].中华中医药杂志,2019,34(6):2593-2598.
[10] 林嘉辉,陈炳艺,龙美兵,等.龟甲胶和鹿角胶含药血清对豚鼠骨关节炎软骨细胞JNK及 p38 MAPK基因表达的影响[J].中国中医骨伤科杂志,2016,24(10):1-4.
[11] 陈炳艺,陈泽华,林嘉辉,等.龟甲胶、鹿角胶调控MKK基因表达促进豚鼠OA软骨细胞增殖的研究[J].中国骨质疏松杂志,2016,22(7):805-808.
[12] 杜江,黄远鹏,李奕修,等.龟鹿二仙胶及其拆方对去势骨关节炎大鼠血清雌二醇浓度及膝关节软骨细胞Ⅱ型胶原表达的影响[J].中医正骨,2013,25(3):11-20.
[13] GOLOB A L,LAYA M.Osteoporosis:screening,prevention,and management[J].Med Clin North Am,2015,99(3):587-606.
[14] WADA H,ASO K,IZUMI M,et al.The effect of postmenopausal osteoporosis on subchondral bone pathology in a rat model of knee osteoarthritis[J].Sci Rep,2023,13(1):2926.
[15] WU P Y,CHEN W,HUANG H,et al.Morinda officinalis polysaccharide regulates rat bone mesenchymal stem cell osteogenic-adipogenic differentiation in osteoporosis by upregulating miR-21 and activating the PI3K/AKT pathway[J].Kaohsiung J Med Sci,2022,38(7):675-685.
[16] WEI W,CAI M,YU S,et al.Effect of magnetic nanoparticles on hormone level changes during perimenopausal period and regulation of bone metabolism[J].Cell Mol Biol(Noisy-le-grand),2022,68(12):91-96.
[17] JIN C,TAN K,YAO Z,et al.A novel anti-osteoporosis mechanism of VK2:interfering with ferroptosis via AMPK/SIRT1 pathway in type 2 diabetic osteoporosis[J].J Agric Food Chem,2023,71(6):2745-2761.
[18] XIAO J,LI W,LI G,et al.STK11 overexpression prevents glucocorticoid-induced osteoporosis via activating the AMPK/SIRT1/PGC1α axis[J].Hum Cell,2022,35(4):1045-1059.
[19] KIM D Y,KO S H.Common regulators of lipid metabolism and bone marrow adiposity in postmenopausal women[J].Pharmaceuticals(Basel),2023,16(2):322.